FDA NDC Directory · JSON-LD · Markdown

JAKAFI XR

NDC 50881-033 · HUMAN PRESCRIPTION DRUG · TABLET, EXTENDED RELEASE

Generic nameruxolitinib
Labeler / ManufacturerIncyte Corporation
Marketing categoryNew Drug Application (innovator) · App NDA217180
Dosage form / routeTABLET, EXTENDED RELEASE · ORAL
Active ingredientsRUXOLITINIB (33 mg/1)
Marketing started20260501
Package count1

External sources

Source: openFDA. Public-domain (CC0).